<?xml version="1.0" encoding="UTF-8"?>
<p id="P10">CC-486 is a novel oral formulation of azacitidine that allows for prolonged azacitidine exposure and sustained DNA hypomethylation over the entire 28-day treatment cycle by using extended dosing schedules [
 <xref rid="R21" ref-type="bibr">21</xref>,
 <xref rid="R22" ref-type="bibr">22</xref>]. Here, we report final results of a prospective phase I/II dose-finding study of CC-486 maintenance treatment after alloSCT in patients with AML or MDS.
</p>
